Ono’s $2.4B Deciphera buy adds two cancer therapies, grows U.S. presence

With its planned $2.4 billion acquisition of Deciphera, Japanese pharma Ono would gain two oncology therapies — one approved, one on the brink of FDA submission — while also deepening its presence in the U.S. as part of a global expansion.

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) proposed to pay $25.60 per share to acquire Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH). The price represents a 75% premium over Friday’s close...